Company intelligence / Profile preview

ONL Therapeutics

Ann Arbor, Michigan, United Statesonltherapeutics.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

ONL Therapeutics has demonstrated in clinical trials that its lead candidate, ONL1204 Ophthalmic Solution—a first-in-class small peptide Fas inhibitor—can reduce the rate of growth of geographic atrophy lesions in AMD patients and shows promise in protecting retinal cells from death and inflammation. The compound has orphan drug designation for retinal detachment. A consistent treatment effect was observed in early clinical studies comparing treated versus untreated eyes.

Therapeutic areas: Ophthalmology
Modalities: Small peptides (specifically a Fas inhibitor peptide)Small molecules
Industry: Biotech

Drug pipeline

1 asset

xelafaslatide

Partnerships

Johnson & Johnson’s Specialty Ophthalmology R&D team provides input to ongoing clinical development plans.

Beyond the preview

Go deeper on ONL Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONL Therapeutics.

Explore the full profile